1、Bristol-Myers Squibb has posted net income of $645 million for the fourth quarter, up almost 9%, but revenues fell 23%, battered by generic competition to the bloodthinner blockbuster Plavix.
百时美施贵宝公布了第四季度的净收入为645,000,000美元，上升了9个百分点，但是由于血液稀释药物拳头产品波立维受到的竞争，营业收入下降了23%。
2、Group sales reached $4.19 billion, with Plavix (clopidogrel) collapsing 97% to just $49 million. The drug lost patent protection in USA in May, two months after generics of the antihypertensive Avapro (irbesartan) were approved across the pond. The latter drug's sales fell 57% to $84 million.
团队销售达到4,190,000,000美元，尽管波立维下降97%而只有49,000,000美元。波立维五月份在美国失去了专利保护。而在这之前两个月，非专利药物伊贝沙坦获批。伊贝沙坦的销售额下降57%至84,000,000美元。
3、Sales of the antipsychotic Abilify (aripiprazole) rose 11% to $819 million and as for the firm's HIV drugs, the Sustiva (efavirenz) franchise decreased 7% to $383 million, and Reyataz (atazanavir) was down 5% to $394 million. Revenues from Baraclude (entecavir) for hepatitis B climbed 22% to $357 million.
抗精神病药阿立哌唑的销售攀升11个百分点达到819,000,000美元，至于抗艾滋病毒药物，特许经营的依非韦伦营业额为383,000,000美元，下降7%，阿扎那韦394,000,000美元，下降5%。抗乙型肝炎药物恩替卡韦的收入攀升22%达357,000,000美元。
4、Sprycel (dasatanib) for leukaemia leapt 24% to $281 million, while Orencia (abatacept) for rheumatoid arthritis increased 26% to $325 million. The cancer agent Erbitux (cetuximab) fell 6% to $171 million, while the melanoma drug Yervoy (ipilimumab) soared 47% to $211 million. The diabetes drugs Onglyza (saxagliptin) and Kombiglyze (saxagliptin/metformin) together delivered $198 million, up 29%.
白血病药物达沙替尼营业额跃升24%至281,000,000美元，风湿性关节炎药物阿巴西普上升26%达325,000,000美元。癌症药剂爱必妥的销售下降6%，为171,000,000美元，而黑色素瘤药物伊匹单抗却飙升47%到达211,000,000美元。药物Onglyza和Kombiglyze共计198,000,000美元，上升29%。
5、Chief executive Lamberto Andreotti said that the company ended "an important year of transition” strongly with regulatory approvals for the oral anticoagulant Eliquis (apixaban) and the diabetes drug Forxiga (dapagliflozin). He added that in 2012, B- "continued to build the post-Plavix portfolio and operating structure that provide a solid foundation for our future growth".
安德雷奥蒂的董事长说到，公司很好地完成了这一年的过渡，拿到了口服抗凝血药阿哌沙班和糖尿病药达格列净的注册审批。他补充到，B-MS“继续建造一个类似波立维一样的产品组合和运营结构，为我们将来的发展奠定了雄厚的基础。”
> > > 正文
分享到：
百时美施贵宝很好地应对了波立维的销售下滑
2013-01-27 20:55:51 来源： 作者： 评论： 点击：
如果您对"百时美施贵宝很好地应对了波立维的销售下滑"有疑问，可以咨询在线专家
